"Neuromuscular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
| Descriptor ID |
D009465
|
| MeSH Number(s) |
D27.505.696.663.700
|
| Concept/Terms |
Neuromuscular Effect- Neuromuscular Effect
- Effect, Neuromuscular
- Neuromuscular Effects
- Effects, Neuromuscular
|
Below are MeSH descriptors whose meaning is more general than "Neuromuscular Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuromuscular Agents".
This graph shows the total number of publications written about "Neuromuscular Agents" by people in this website by year, and whether "Neuromuscular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2015 | 2 | 0 | 2 |
| 2018 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuromuscular Agents" by people in Profiles.
-
Lapane KL, Hume AL, Morrison RA, Jesdale BM. Prescription analgesia and adjuvant use by pain severity at admission among nursing home residents with non-malignant pain. Eur J Clin Pharmacol. 2020 Jul; 76(7):1021-1028.
-
Chiu SY, Patel B, Burns MR, Legacy J, Wagle Shukla A, Ramirez-Zamora A, Deeb W, Malaty IA. High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
-
McAlindon TE, Schmidt U, Bugarin D, Abrams S, Geib T, DeGryse RE, Kim K, Schnitzer TJ. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study. Osteoarthritis Cartilage. 2018 10; 26(10):1291-1299.
-
Filippakis A, Ho DT, Small JE, Small KM, Ensrud ER. Radiation-Induced Painful Neurogenic Hypertrophy Treated With Botulinum Toxin A. J Clin Neuromuscul Dis. 2018 Mar; 19(3):135-137.
-
Tian C, Wong BL, Hornung L, Khoury JC, Miller L, Bange J, Rybalsky I, Rutter MM. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016 11; 26(11):760-767.
-
Lee HN, Sawnani H, Horn PS, Rybalsky I, Relucio L, Wong BL. The Performance of the Upper Limb scores correlate with pulmonary function test measures and Egen Klassifikation scores in Duchenne muscular dystrophy. Neuromuscul Disord. 2016 Apr-May; 26(4-5):264-71.
-
Alvarez CA, Mortensen EM, Makris UE, Berlowitz DR, Copeland LA, Good CB, Amuan ME, Pugh MJ. Association of skeletal muscle relaxers and antihistamines on mortality, hospitalizations, and emergency department visits in elderly patients: a nationwide retrospective cohort study. BMC Geriatr. 2015 Jan 27; 15:2.
-
Mahmoud BH, Burnett C, Ozog D. Prospective randomized controlled study to determine the effect of topical application of botulinum toxin A for crow's feet after treatment with ablative fractional CO2 laser. Dermatol Surg. 2015 Jan; 41 Suppl 1:S75-81.
-
Ellsworth P, Travis M. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder. Urol Nurs. 2014 Jul-Aug; 34(4):165-71.
-
Adelowo A, Hacker MR, Shapiro A, Modest AM, Elkadry E. Botulinum toxin type A (BOTOX) for refractory myofascial pelvic pain. Female Pelvic Med Reconstr Surg. 2013 Sep-Oct; 19(5):288-92.